Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 11

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,155 result(s) found for: 11. Displaying page 299 of 608.
    EudraCT Number: 2019-004987-23 Sponsor Protocol Number: RAS-Triplet Start Date*: 2020-05-22
    Sponsor Name:UMC Utrecht
    Full Title: A Dose-Escalating Phase I/II Study in Patients with RAS-Mutated Metastatic Colorectal Cancer to Investigate Safety and Clinical Activity of the Triple Combination of: MEK-inhibitor binimetinib, Pan...
    Medical condition: colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003926-18 Sponsor Protocol Number: MITO28/MANGOOV4 Start Date*: 2018-11-19
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: A phase II clinical trial of Pembrolizumab in combination with Carboplatin-Paclitaxel in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer: MITO28/MANG...
    Medical condition: advanced (stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000309-21 Sponsor Protocol Number: PREDICT_Trial_Amd_04 Start Date*: 2013-10-01
    Sponsor Name:Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Full Title: Antibiotic Prophylaxis and Renal Damage In Congenital abnormalities of the kidney and urinary Tract
    Medical condition: Infants with vesicoureteral reflux grade III-V, started before the first symptomatic infection.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10047371 Vesicoureteral reflux LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) LT (Completed) ES (Ongoing) DE (Ongoing) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001032-22 Sponsor Protocol Number: AGI-134.FIM.101 Start Date*: 2019-01-21
    Sponsor Name:Agalimmune Ltd.
    Full Title: A phase I/IIa, multicentre, open label study designed to evaluate the safety and tolerability of escalating doses of AGI-134 in unresectable/metastatic solid tumours.
    Medical condition: metastatic unresectable solid tumours
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-002330-23 Sponsor Protocol Number: 9794 Start Date*: 2017-11-24
    Sponsor Name:University hospital of Montpellier
    Full Title: HEPATIC ARTERIAL INFUSION OF GEMCITABINE-OXALIPLATIN FOR SECOND-LINE THERAPY IN NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA: A MULTICENTRIC SINGLE-ARM PHASE II STUDY
    Medical condition: The combination of gemcitabine and oxaliplatin intra-arterial as second-line therapy can greatly improve the Objective Response Disorder (ORT) at 4 months
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036706 Primary liver cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000417-37 Sponsor Protocol Number: ARRAY-818-202 Start Date*: 2019-07-16
    Sponsor Name:Array BioPharma Inc.
    Full Title: A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer
    Medical condition: BRAF V600E-mutant Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003151-21 Sponsor Protocol Number: INT 35/06 Start Date*: 2006-08-31
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Study to compare the tolerability of slow release oxycodone versus slow release morphine in the treatment of severe cancer pain. The study is geared towards a clinical practice improvement.
    Medical condition: Advanced cancer patient with severe cancer pain
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033371 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022486-10 Sponsor Protocol Number: MT-102-2001 Start Date*: 2010-11-02
    Sponsor Name:Myotec Therapeutics Limited
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subject...
    Medical condition: Cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004076-13 Sponsor Protocol Number: 5 Start Date*: 2006-11-28
    Sponsor Name:Huvud- hals- lung- och hudcancer, Tema Cancer Karolinska Universitetssjukhuset
    Full Title: Secar I Part I: A study of MTD of Sodium selenite in patients with advanced carcinoma. A phase I study. Amendment 5: continuous treatment
    Medical condition: Patients with stage III or IV cancer in whom first and second line treatment have been given but who have tumours that are still progressing, giving symptomes. The patients must be in a fairly good...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004751-23 Sponsor Protocol Number: CA2099TT Start Date*: 2018-11-05
    Sponsor Name:AMC
    Full Title: A Phase 1b-2 study of Mitomycin-C / Capecitabine chemoradiotherapy combined with Ipilumimab and Nivolumab or Nivolumab monotherapy as bladder sparing curative treatment for muscle Invasive bladder...
    Medical condition: Muscle invasive non-metastatic bladder cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004311-40 Sponsor Protocol Number: TORCH Start Date*: 2018-05-24
    Sponsor Name:Academic Medical Center
    Full Title: Tranexamic Acid to Prevent Operation in Chronic Subdural Hematoma
    Medical condition: Chronic Subdural Hematoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10049163 Chronic subdural hematoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-006004-16 Sponsor Protocol Number: 03PDE2020 Start Date*: 2021-07-16
    Sponsor Name:Celon Pharma S.A.
    Full Title: Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A inhibitor) in Patients with Parkinson's Diseas...
    Medical condition: Levodopa-induced dyskinesia in Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004758-39 Sponsor Protocol Number: ESR-18-13485 Start Date*: 2019-06-12
    Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA
    Full Title: A PHASE II STUDY OF CAPECITABINE PLUS CONCOMITANT RADIATION THERAPY FOLLOWED BY DURVALUMAB (MEDI4736) AS PREOPERATIVE TREATMENT IN RECTAL CANCER
    Medical condition: Locally advanced (T3-4 N0-1) rectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038019 Rectal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002495-34 Sponsor Protocol Number: GETUG 17/0702 Start Date*: 2007-09-25
    Sponsor Name:FNCLCC
    Full Title: Etude randomisée multicentrique comparant une radiothérapie adjuvante immédidate associée à une hormonothérapie courte par analogue LH-RH (Décapeptyl LP®) vs une radiothérapie différée à la rechut...
    Medical condition: L’étude s’adresse aux patients opérés par prostatectomie radicale pour un cancer de prostate pT3 R1 pN0 ou pNx et avec un PSA post-opératoire indosable. Elle vise à comparer l’efficacité sur la sur...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001186 Adenocarcinoma of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000652-28 Sponsor Protocol Number: AIEOP_LAM_2013 Start Date*: 2015-02-04
    Sponsor Name:A.I.E.O.P.
    Full Title: Study Protocol LAM 2013/01
    Medical condition: pediatric patient with acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10024349 Leukemia myeloid LLT
    Population Age: Newborns, Infants and toddlers, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000987-14 Sponsor Protocol Number: TRAMANT-01 Start Date*: 2017-10-20
    Sponsor Name:AZIENDA OSPEDALIERA PER L'EMERGENZA CANNIZZARO
    Full Title: Phase II Study: Maintenance therapy with Trabectedin after combination therapy Liposomal Doxorubicin plus Trabectedin vs Liposomal Doxorubicin plus Trabectedin in patients affected by relapsed ovar...
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033160 Ovarian epithelial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003235-23 Sponsor Protocol Number: RBM 04-34 Start Date*: 2009-01-09
    Sponsor Name:Inserm
    Full Title: Essai randomisé multicentrique de phase II d'évaluation immunologique d'une stratégie vaccinale de type "prime boost" associant une administration du vaccin conjugué anti-pneumococcique à S0 suivie...
    Medical condition: Déficit immunitaire commun variable
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010112 Common variable immunodeficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002526-23 Sponsor Protocol Number: CS2514-2017-0004 Start Date*: 2019-05-07
    Sponsor Name:Entasis Therapeutics
    Full Title: A Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter baumannii-calcoacetic...
    Medical condition: Infections Caused by Acinetobacter baumannii-calcoaceticus Complex
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10003999 Bacteremia LLT
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    20.1 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    20.0 10021881 - Infections and infestations 10076918 Hospital acquired pneumonia LLT
    20.1 10021881 - Infections and infestations 10065153 Ventilator associated pneumonia LLT
    20.0 10021881 - Infections and infestations 10078408 Surgical site infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004868-57 Sponsor Protocol Number: UC-0105/1815 Start Date*: 2019-09-02
    Sponsor Name:UNICANCER
    Full Title: Phase 2, Open label Study of DS-8201a, an Anti-HER2-AntIbody Drug Conjugate (ADC) for advanced BreaSt Cancer patients, with biomarkers analysis to characterize response/resistance to therapY
    Medical condition: Adult patients with advanced breast cancer after at least a first line of chemotherapy in metastatic setting: -if HER2 IHC3+ or IHC2+/ISH+ resistant to trastuzumab and TDM-1 -if HER2 IHC0+ or IHC...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001780-27 Sponsor Protocol Number: HTA-HG5-04 Start Date*: Information not available in EudraCT
    Sponsor Name:Holostem Terapie Avanzate s.r.l.
    Full Title: OPEN-LABEL, UNCONTROLLED, CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED FOR RESTORATION OF E...
    Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient’s qu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 01:03:04 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA